NEWSWIRETODAY Press Release& Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: Frost & Sullivan
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Adoption of In Silico Tools in Drug Discovery Accelerates Time to Market and Confers Cost Advantages Notes Frost & Sullivan - Due to the decrease in the roll out of blockbuster drugs in recent years, the focus has intensified on the development of in silico screening systems
Adoption of In Silico Tools in Drug Discovery Accelerates Time to Market and Confers Cost Advantages Notes Frost & Sullivan

 

NewswireToday - /newswire/ - Mountain View, CA, United States, 2010/07/30 - Due to the decrease in the roll out of blockbuster drugs in recent years, the focus has intensified on the development of in silico screening systems.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

There is greater emphasis on reducing the cycle time significantly to shorten the time to market for new drugs. The limited time frame granted for the generation of blockbuster drugs is an important driver for the development of in silico tools.

New analysis from Frost & Sullivan (technicalinsights.frost.com), Bioinformatics in Drug Discovery, finds that while there is a clear focus on differentiation of technology in terms of the applications in the in silico space, there is an equal focus on cost-based strategies in the industry.

If you are interested in a virtual brochure on this study, please send an email to Sarah Saatzer, Corporate Communications, at sarah.saatzer[.]frost.com, with your full name, company name, job title, telephone number, company email address, company website, city, state and country.

"The pressure is intensifying on pharmaceutical companies to develop new drugs, which are capable of replacing older ones that are going off patent," notes Technical Insights Industry Analyst Bhuvaneashwar Subramanian. "With the cost of drug discovery and development escalating every year, companies are now looking at using bioinformatics to lessen the time for generating drugs."

Not surprisingly, the cost for target discovery and validation together accounts for a little over 42 percent of the total drug discovery expense. This is essentially because the process of target discovery and validation depends on the robustness of the software that is developed to model the desired range of products for the purpose of drug discovery.

The cost of the products in in silico drug discovery varies according to the applications for which they are deployed. About 50 to 90 percent of the cash outflow is channeled toward the key steps of algorithm development, proof of concept studies and formulation of the final application.

More often than not, the success of a drug discovery experiment depends upon the effectiveness of the in silico tools employed to assess the varied aspects of the drug. These include 3D structures of the ligand and the protein, assessing ADMET (absorption, distribution, metabolism, elimination, toxicology) profiles, docking affinities and most importantly, interaction of the drug, ligand and pharmacology profiles. All of these components, integral to the drug discovery space, can be effectively determined through the usage of specific in silico software.

Although several tools have been in use, the lack of standards in the industry has made it difficult to validate these tools. Hence, there arises a need to develop standards that would allow efficient means of organizing, analyzing, and storing data. Additionally, the large amount of data generated through various research processes highlights the need for standard data formats and interfaces. Different annotation systems use different standards, which lead to lack of coordination of available data.

Lack of integration of biological data can result in the same data being replicated by several scientists across the globe. Thus, the industry must look at developing standard data formats that could help prevent such issues.

The advent of cloud computing has made it possible to develop coding across a shared space. The ability to do so could bring down costs drastically, with the availability of several operational modules essential to generate a drug discovery software in the most efficient manner. As trials involve a major portion of development costs, cost reduction can be achieved through open advertising of the software across specialized forums.

"A pool of researchers in the drug discovery community could be engaged to try the efficacy of the software," says Subramanian. "In doing so, a fundamental advantage that is gained is the ability to understand the existing customer base and thereby expedite software efficiency."

Bioinformatics in Drug Discovery, a part of the Technical Insights subscription, provides an overview of key technology trends in this space and the potential implications on the sustainability of businesses in the drug discovery segment.

Technical Insights is an international technology analysis business that produces a variety of technical news alerts, newsletters, and research services.

About Frost & Sullivan
Frost & Sullivan (frost.com), the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 40 offices on six continents.

Bioinformatics in Drug Discovery / D1FC

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Adoption of In Silico Tools in Drug Discovery Accelerates Time to Market and Confers Cost Advantages Notes Frost & Sullivan

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Sarah Saatzer 
210-477-8427 sarah.saatzer[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

Celltrion Pharm Selects TrackWise QMS for Scalability and Data Integrity
Ipsen Adds Another Program into its Pre-clinical R&D Oncology Pipeline through An Exclusive Worldwide Collaboration with Accent Therapeutics
Evaxion Biotech Lauded by Frost & Sullivan for Helping Develop Highly Targeted Therapies with its AI Immunology Platforms
Kyowa Hakko Acclaimed by Frost & Sullivan for its Non-GMO, Allergen-free, Immune Support Paraprobiotic Ingredient, IMMUSE™
DSM to Acquire First Choice Ingredients to Accelerate Growth in Food and Beverage
STEMCELL Technologies Launches Human Pluripotent Stem Cell Characterization and Banking Services in Partnership with WiCell
Biocon Selects TrackWise to Enable Enterprise Quality Management Across Global Biopharmaceutical Operations
STEMCELL Technologies and Hubrecht Organoid Technology to Partner on Non-Oncology Organoid Drug Screening Services
Ipsen and Exicure Enter into Exclusive Collaboration Targeting Rare Neurodegenerative Disorders
Ipsen Strengthens its Pre-clinical Oncology Pipeline with An Exclusive Worldwide-collaboration with BAKX Therapeutics, Inc. for BKX-001
Pharma and Biotech to Highly Invest in RNA Therapeutics to Expedite Research & Development across the Globe Finds Frost & Sullivan
Parexel Commended by Frost & Sullivan for Developing a Flexible and Agile Delivery Model to Improve Clinical Trial Outcome
Ipsen and IRLAB Enter Exclusive Worldwide Licensing Agreement Aimed to Improve the Lives of People Living with Parkinson’s Disease
Exelixis and Ipsen Announce Cabozantinib in Combination with An Immune Checkpoint Inhibitor Significantly Improved Progression
Ipsen Opts-in to Join Exelixis with Ongoing Development of Cabometyx® for People Living with A Form of Thyroid Cancer

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  Limelon Advertising, Co.

Visit  RightITnow, Inc.





 
  ©2021 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are proudly NOT affiliated with USA TODAY (usatoday.com)